Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-202 in Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer
NCT01734681Phase 2Withdrawn
- Sponsor
- Inspyr Therapeutics
- Start
- May 2013
- Primary completion
- Jan 2015
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of mipsagargin in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Inspyr Therapeutics. Planned start May 2013; status: withdrawn.
02
Drugs
mipsagargin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01734681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01734681.